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Defining the characteristics of HIV-specific CD8 T cell responses that lead to viral control is crucial for vaccine development.
We evaluated the differential impact of magnitude, polyfunctional capacity, and specificity of the CD8 response at approxi-
mately 6 months postinfection on the viral set point at 12 months in a cohort of HIV-infected individuals. High frequencies of
Gag and Nef responses endowed with four functions were the best predictors of a low viral set point.
Understanding the attributes of an immune response that re-sults in control of HIV replication is critical for designing an
HIV vaccine capable of eliciting such a response (1). A robust
predictor of viral control would accelerate vaccine development
significantly, since we currently rely on infection outcomes in
lengthy, large clinical trials. Simple measures such as the magni-
tude of CD8 gamma interferon (IFN-) T cell responses to HIV
failed to associate with control of viral replication (2, 3). However,
several quantitative or qualitative characteristics of HIV-specific
CD8 T cells have been correlated with HIV control, including
their capacity to (i) develop breadth with respect to Gag responses
(4, 5); (ii) target conserved regions of the HIV proteome (6); (iii)
secrete multiple cytokines simultaneously (polyfunctionality) (7);
(iv) maintain enhanced proliferative or killing ability (8–10); (v)
recognize peptide with high avidity (11, 12); and (vi) exhibit par-
ticular memory phenotypes (13, 14). The majority of these corre-
lates have been identified in HIV long-term nonprogressors
(LTNPs) or in large cross-sectional studies of chronic HIV infec-
tion. We examined the characteristics of HIV-specific CD8 cells
in a prospective cohort of individuals during early HIV infection
with viral loads at various set points.
The purpose of this study was to identify the attributes of early
CD8 responses that predicted a reduced viral set point (VSP), a
well-established indicator of the rate of HIV disease progression
(15). In order to dissect the relative contribution to viral control of
the quantity as opposed to the quality of the CD8 T cell response,
we analyzed the influence of the magnitude, specificity, and poly-
functional profile of HIV-specific cells on HIV load at 12 months
postinfection as an estimate of the VSP. T cell responses were
measured at approximately 6 months postinfection in a cohort of
individuals infected with HIV-1 clade C (CAPRISA 002 acute in-
fection cohort; see Table S1 in the supplemental material for clin-
ical characteristics) (16). Peripheral blood mononuclear cells
(PBMC), collected at a median of 30 weeks postinfection (range,
18 to 42 weeks), were stimulated for 6 h in the presence of Gag
(n  21 individuals), Nef (n  15), or Env (n  15) peptide pools
spanning HIV-1 clade C. Using polychromatic flow cytometry,
HIV-specific CD8 T cell responses were assessed by measuring
five distinct functions, namely, those corresponding to tumor
necrosis factor alpha (TNF-), IFN-, interleukin-2 (IL-2), MIP-1,
and CD107a (Fig. 1A). We first compared the VSPs between indi-
viduals with and without a detectable CD8 response at 6 months
for each of the peptide pools tested. We found no significant dif-
ferences in the VSP between responders and nonresponders for
any of the peptide pools (Fig. 1B). When we investigated the over-
all relationship between the combined magnitudes of Gag-, Nef-,
and Env-specific CD8 T cell responses with the VSP, no associ-
ation was found (P  0.09, r  0.45; data not shown). However,
when HIV responses were analyzed based on their individual pro-
tein specificities, the frequencies of Gag- and Nef-specific CD8 T
cell responses inversely correlated with VSP (P  0.0005 [r 
0.7] and P  0.006 [r  0.69], respectively; Fig. 1C). The
combined magnitudes of Gag- and Nef-specific CD8 T cell val-
ues also correlated inversely with VSP (P  0.011, r  0.63; data
not shown). No such association was observed with the frequen-
cies of Env-specific responses. Of note, there was no association
between the concomitant HIV load and the frequency of HIV-
specific responses to any of the peptide pools tested (data not
shown). Collectively, these data indicate that the effect of the mag-
nitude of HIV-specific CD8 T cell responses (as measured by five
functions) on viral replication control is dependent on the speci-
ficity of the targeted HIV protein, where high frequencies of Gag
and Nef responses were associated with a lower VSP whereas Env
responses had no impact.
To evaluate the relationship between the functional quality of
HIV-specific CD8 T cells and the VSP, we next assessed the poly-
functional quality of Gag-specific T cell responses at 6 months
postinfection, by grouping responding individuals with different
VSPs: VSP  10,000 HIV RNA copies/ml (median, 1,060 HIV
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FIG 1 Frequencies and polyfunctional capacities of HIV-specific CD8 T cells in response to Gag, Nef, and Env peptide pools at 6 months postinfection. (A)
Representative flow cytometry plots of a Gag-specific CD8 T cell response as measured by the production of TNF-, IFN-, IL-2, and MIP-1 and expression
of CD107a. The top panel corresponds to unstimulated PBMC (NS) and the bottom panel to cells stimulated with a Gag peptide pool. Numbers represent the
frequencies of cytokine-producing cells expressed as percentages of the total memory CD8 T cell population. Total memory CD8 T cells were gated based on
the exclusion of naive CD8 T cells (CD45RO CD27). (B) Comparison between responders (R) and nonresponders (NR) of HIV set points (VSP) at 12
months for each of the tested peptide pools (Gag responses are depicted with red circles [n  21], Nef responses are depicted with blue circles [n  15], and Env
responses are displayed with open circles [n  15]). A positive cytokine response was defined as being at least twice the background (no antigen, only
costimulatory antibodies) and 	0.05% after background subtraction. Medians are shown as horizontal bars. The viral set point was calculated as the geometric
mean of viral load measurements at three time points at week 52 
 6 weeks postinfection (46 to 58 weeks) in order to minimize possible spurious viral load
measurements. (C) Association of the magnitude of HIV-specific responses producing any of the five functions measured (i.e., TNF-, IFN-, IL-2, CD107a, and
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RNA copies/ml; n  6), 10,000  VSP  50,000 HIV RNA cop-
ies/ml (median, 37,690 HIV RNA copies/ml; n  7), and VSP 	
50,000 HIV RNA copies/ml (median, 94,940 HIV RNA copies/ml;
n  5). The proportion of Gag-specific CD8 T cells endowed
with 4 functions (TNF- positive [TNF-] IFN- CD107a
MIP-1) was significantly higher in responders with the lowest
VSP than in individuals with the highest VSP (median, 10.3%
versus 0.2%; P  0.008) (Fig. 1D). The proportion of Gag-specific
CD8 T cells endowed with 2 functions (IFN- CD107a,
CD107a MIP-1, or IFN- MIP-1), in turn, was signifi-
cantly higher in individuals with the highest VSP than in those
with VSP  10,000 and 10,000  VSP  50,000 HIV RNA copies/
ml. We performed the same analysis for Nef and found a greater
proportion of 4-function cells in the group with the lowest VSP
(although the proportion was not significantly different from that
determined for the group with the highest VSP) and a trend to-
ward a higher proportion of Nef-specific CD8 T cells endowed
with 2 functions in individuals with the highest VSP (P  0.07;
data not shown). The smaller number of responders for Nef (n 
11) may explain why these values do not reach statistical signifi-
cance.
In addition to assessing the proportions of Gag- and Nef-spe-
cific cells with 4 functions (as a proportion of the total Gag or Nef
response), we measured the magnitude of the 4-function popula-
tion (as a frequency of total memory CD8 response). We found
a significant association between the frequency of 4-function
CD8 T cells and VSP in response to Gag and Nef (P  0.0002
[r  0.74] and P  0.0017 [r  0.75], respectively; Fig. 1E). As
with the total-magnitude results, no such association was ob-
served with Env-specific 4-function responses. In addition, there
was no association between the presence of protective HLA alleles
(see Table S1 in the supplemental material) and the magnitude of
response, proportion, or frequency of 4-function cells (data not
shown). Thus, these data extend our current understanding of the
importance of maintaining highly polyfunctional CD8 T cells for
viral control (7, 11) and highlight the fact that this association may
depend on the targeting of specific HIV proteins.
In order to define the specificity and sensitivity of Gag- and
Nef-specific CD8 T cell response measurements at 6 months
postinfection for 12-month VSP prediction, we calculated re-
ceiver operating characteristics (ROC) curves comparing the fre-
quency of total Gag- or Nef-specific CD8 T cell responses, the
proportion of 4-function Gag- or Nef-specific responses, and the
frequency of 4-function Gag- or Nef-specific responses. All three
measurements were associated with significant performance char-
acteristics for the prediction of VSP for Gag (Fig. 2), while this was
true for the frequency of total and 4-function cells for Nef (Fig. 2A
to C). However, the frequency of 4-function Gag- and Nef-specific
CD8 T cells best predicted VSP (AUC of 0.89 [P  0.0065] and
95% confidence interval [CI] of 0.74 to 1.04 for Gag and AUC of
0.9 [P  0.014] and 95% CI of 0.7 to 1.09 for Nef; Fig. 2C). The
threshold values of the frequencies of total and 4-function Gag-
specific CD8 T cells, identified to maximize discrimination be-
tween individuals with VSPs lower or higher than 10,000 HIV
RNA copies/ml, were 0.7% and 0.08%, respectively (Fig. 2F). For
Nef, these values were 1.2% and 0.15%, respectively (data not
shown).
In conclusion, both the frequency and the polyfunctional ca-
pacity of Gag- and Nef-specific CD8 T cell responses during early
HIV infection were associated with a lower VSP, and we identified
the frequency of a specific subset of Gag- and Nef-specific CD8 T
cells, namely, cells simultaneously expressing TNF-, IFN-,
CD107a, and MIP-1, as the best predictor. Although many early
studies did not find an association between the magnitude of HIV-
specific responses and viral load (2, 3), their frequencies were as-
sessed using the IFN- enzyme-linked immunosorbent spot
(ELISpot) assay. However, five functions were measured in this
study, enabling a more accurate quantification of the overall mag-
nitude of HIV-specific responses. In fact, measuring IFN- only
would have missed 60% of the responses to HIV (data not shown),
with MIP-1 being the most abundant cytokine produced, in
agreement with other studies (7). Our findings accord with recent
data (17) showing that viral control of HIV-2 was significantly
associated with a high-magnitude, polyfunctional Gag-specific
CD8 T cell response. This further confirms the prevailing notion
that immune responses to Gag possess enhanced antiviral potency
compared to other specificities, likely as a result of its conservation
and the higher rate of viral escape that exacts a fitness cost for HIV
(18–20). More intriguing is the association we found with Nef-
specific responses and lower VSP. Recently, Nef responses have
been implicated in mediating control of simian immunodefi-
ciency virus (SIV) in macaques (21, 22) and HIV in viral control-
lers (23, 24). In addition, there are convincing data that HLA-
selected polymorphisms in Nef revert to the wild type at a high rate
upon transmission to non-HLA-matched hosts, strongly suggest-
ing that these are escape mutations resulting from immune selec-
tive pressure that result in a fitness cost for HIV (25). Thus, our
finding is consistent with mounting evidence of a role for CD8 T
cell responses to Nef in viral control, which has implications for T
cell vaccine design.
This study had several limitations. We were limited by sample
availability to measuring CD8 responses using peptide pools
rather than individual peptides. We thus cannot differentiate be-
tween epitope responses known to result in a fitness cost to HIV
and conserved epitopes within the protein-specific pools. In addi-
tion, we had insufficient sample to determine polymerase (Pol)
responses and their relationship with the viral set point. Given the
observation that Pol responses can be frequent and dominant and
can target highly conserved epitopes (26–28), this warrants fur-
ther investigation. Furthermore, while we can offer predictive val-
ues for frequencies of highly functional Gag and Nef-specific
CD8 T cells for a lower viral set point, we cannot establish cau-
MIP-1) at 6 months postinfection with VSP at 12 months. One individual who was a nonresponder for all three proteins was excluded from the analysis. (D)
Comparison of the polyfunctional profiles of Gag-specific responses measured at 6 months postinfection in the 18 responding individuals with VSP  10,000
RNA copies/ml (n  6), 10,000  VSP  50,000 RNA copies/ml (n  7), and VSP 	 50,000 RNA copies/ml (n  5). The slices of the pies correspond to the
proportions of Gag-specific CD8 T cells (as a frequency of the total Gag response) expressing 1, 2, 3, 4, or 5 functions, calculated using Boolean gating. Statistical
comparisons were determined using a nonparametric one-way analysis of variance (ANOVA; Kruskal-Wallis test). *, P  0.05. (E) Association between the
magnitude of HIV-specific CD8 T cells endowed with four functions (as a frequency of total memory CD8 T cells) at 6 months postinfection and VSP at 12
months. The individual who was a nonresponder for all three proteins was excluded from this analysis. Statistical comparisons were determined using nonpara-
metric Mann-Whitney U-tests and two-tailed nonparametric Spearman rank correlations for statistical associations.
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sality. Lastly, all participants in our cohort were African females
infected with HIV-1 clade C; testing the generalizability of our
findings in additional populations in warranted.
Thus, while the total CD8 T cell response to all HIV antigens
does not correlate with VSP, a particular component of this re-
sponse does correlate. It is notable that measuring other charac-
teristics of responding cells may further delineate those with the
best functional control, such as perforin expression, recently high-
FIG 2 Sensitivity and specificity of Gag- and Nef-specific CD8 T cell measurements at 6 months postinfection for the prediction of a VSP of 10,000 HIV RNA
copies/ml at 12 months. Receiver operator characteristics (ROC) curves for the total magnitude of the Gag- and Nef-specific CD8 T cell response (as a frequency
of total memory CD8 T cells) (A), the proportion of 4-function cells specific for Gag and Nef (as a frequency of the total HIV responses) (B), and the magnitude
of 4-function Gag- and Nef-specific CD8 T cells (as a frequency of total memory CD8 T cells) (C) with VSP at 12 months are shown. The area-under-the-curve
(AUC) values, P values, and confidence intervals (CI) are shown. The dotted line depicts an AUC of 0.5, representing a random test. (D, E, and F) Specificity/
sensitivity crossover plots showing the optimal threshold (vertical arrow) at which each measurement in response to Gag predicts a VSP of 10,000 HIV RNA
copies/ml, minimizing discrepant results. This value is the threshold that limits the number of false positives (sensitivity) or false negatives (specificity). For
example, in panel F, a frequency of 4-function Gag-specific CD8 T cells of 	0.08% cells at 6 months postinfection predicts a VSP of 10,000 copies/ml with
maximum specificity and sensitivity.
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lighted as a measure of elite control of HIV (29, 30). In line with
this, Yang and colleagues demonstrated that the ability of CD8 T
cells to mediate inhibition of HIV in vitro associated inversely with
viral set point in a cohort of viremic individuals (31).
In summary, by combining measures of magnitude, specificity,
and function of the HIV-specific CD8 T cell response, we iden-
tified a subset of highly polyfunctional cells directed at Gag and
Nef which, when occurring at a high frequency, were associated
with a lower HIV set point. This finding not only substantiates
mechanistic hypotheses of immunological control (32) but also
highlights the importance of eliciting such cells by vaccination to
enable the best outcome following breakthrough infection.
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